Clinical Trial Detail

NCT ID NCT03976323
Title Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-squamous non-small cell carcinoma

Therapies

Pembrolizumab + Pemetrexed Disodium

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Olaparib + Pembrolizumab

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.